HC Wainwright Forecasts Higher Earnings for Microbot Medical

Microbot Medical Inc. (NASDAQ:MBOT) – Investment analysts at HC Wainwright upped their Q2 2026 earnings per share estimates for shares of Microbot Medical in a research note issued to investors on Monday, July 13th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn ($0.06) per share for the quarter, up from their previous estimate of ($0.08). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Microbot Medical’s current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Microbot Medical’s Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.24) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.25) EPS.

Other research analysts have also recently issued reports about the stock. Loop Capital set a $4.00 target price on shares of Microbot Medical in a research report on Wednesday, June 3rd. Wall Street Zen upgraded shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Microbot Medical in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Microbot Medical has an average rating of “Moderate Buy” and a consensus price target of $6.62.

Microbot Medical Stock Down 0.5%

NASDAQ MBOT opened at $1.87 on Wednesday. The company has a quick ratio of 21.93, a current ratio of 22.59 and a debt-to-equity ratio of 0.01. Microbot Medical has a fifty-two week low of $1.60 and a fifty-two week high of $4.67. The business has a 50 day moving average price of $1.89 and a two-hundred day moving average price of $2.11. The stock has a market cap of $125.61 million, a PE ratio of -7.19 and a beta of 1.04.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.30 million.

Institutional Trading of Microbot Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in MBOT. CIBC Private Wealth Group LLC lifted its holdings in Microbot Medical by 137.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,454,000 shares of the biotechnology company’s stock worth $4,435,000 after buying an additional 842,000 shares during the last quarter. Heights Capital Management Inc. bought a new position in shares of Microbot Medical in the 3rd quarter worth about $2,693,000. DNB Asset Management AS grew its position in shares of Microbot Medical by 178.1% during the 4th quarter. DNB Asset Management AS now owns 677,498 shares of the biotechnology company’s stock valued at $1,355,000 after buying an additional 433,869 shares during the last quarter. Cetera Investment Advisers lifted its holdings in Microbot Medical by 44.7% in the first quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 13,099 shares during the last quarter. Finally, Man Group plc bought a new position in shares of Microbot Medical during the fourth quarter valued at approximately $35,000. Institutional investors own 16.30% of the company’s stock.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.